Hims & Hers Health, Inc. (NYSE:HIMS) Receives $21.43 Consensus Price Target from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has been given an average recommendation of “Hold” by the seventeen analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $22.80.

A number of brokerages recently commented on HIMS. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Morgan Stanley initiated coverage on Hims & Hers Health in a report on Tuesday. They issued an “overweight” rating and a $42.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Finally, TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th.

Insider Activity

In other news, CEO Andrew Dudum sold 45,767 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.33, for a total value of $747,375.11. Following the transaction, the chief executive officer now directly owns 67,015 shares of the company’s stock, valued at $1,094,354.95. This represents a 40.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Melissa Baird sold 85,561 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $31.01, for a total transaction of $2,653,246.61. Following the sale, the chief operating officer now owns 630,986 shares of the company’s stock, valued at approximately $19,566,875.86. This represents a 11.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,143,575 shares of company stock valued at $27,724,979 in the last quarter. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its stake in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC lifted its stake in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the 2nd quarter valued at $111,000. CWM LLC increased its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Finally, Quarry LP raised its holdings in shares of Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after buying an additional 2,913 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 8.3 %

Shares of NYSE HIMS opened at $28.55 on Monday. Hims & Hers Health has a twelve month low of $8.09 and a twelve month high of $35.02. The stock has a market cap of $6.24 billion, a price-to-earnings ratio of 64.89 and a beta of 1.25. The company’s fifty day moving average is $25.46 and its 200-day moving average is $21.19.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.04) EPS. On average, research analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.